Used in the development and validation of therapeutic agents targeting von Willebrand Factor (vWF), this antibody serves as a critical reference standard in immunoassays to measure vWF activity and inhibition. It supports the calibration of assays used in diagnosing and monitoring von Willebrand Disease (VWD) and thrombotic thrombocytopenic purpura (TTP). Due to its high specificity, it is employed in pharmacokinetic and pharmacodynamic studies of anti-thrombotic drugs, ensuring consistency in biosimilar development and quality control in biopharmaceutical manufacturing. It also aids in the evaluation of drug interference in clinical testing platforms involving vWF.